Corbus Gets Patent Covering Use of Anabasum for the Treatment of Rare Fibrotic Diseases

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) announced it received a patent from the US Patent and Trademark Office covering the use of pharmaceutical compositions comprising anabasum for the treatment of multiple fibrotic diseases.
As quoted in the press release:

Including the Company’s lead indications: systemic sclerosis, dermatomyositis, cystic fibrosis as well as others. The patent provides intellectual property protection in the United States for the use of anabasum through 2034. This patent follows the recently issued patent 9,801,849 covering uses of anabasum in multiple inflammatory diseases including systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, psoriasis and others.
This patent is part of an expanding and comprehensive portfolio of patents, patent applications and other intellectual property covering the synthesis, manufacturing, formulation and uses of anabasum for a variety of indications including the Company’s lead indications: systemic sclerosis, dermatomyositis, cystic fibrosis and systemic lupus erythematosus. Anabasum is a synthetic oral endocannabinoid-mimetic drug candidate designed to resolve chronic inflammation and fibrosis through the activation of the CB2 receptor to stimulate production of specialized pro-resolving mediators.

Click here to read the full press release.

Source: www.marketwired.com